Pharmaceutical

Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1

Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.

May 3, 2024 - 00:00
Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1
Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.
Read the original article

Tags:

Previous Article

ESCMID 2024: Drug resistance in fungi – a growing issue

Next Article

Novartis acquires Mariana in $1.75bn deal to strengthen radioligand portfolio 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ArsenalBio secures $325m to develop cell therapy programmes

ArsenalBio secures $325m to develop cell therapy progra...

Sep 6, 2024

FDA grants breakthrough therapy status to Arrowhead’s plozasiran

FDA grants breakthrough therapy status to Arrowhead’s p...

Sep 12, 2024

Understanding the role of recombinant insulin in cell culture systems: What the studies say 

Understanding the role of recombinant insulin in cell c...

Apr 14, 2023